Structural Basis of Non-Steroidal Anti-Inflammatory Drug Diclofenac Binding to Human Serum Albumin

Chemical Biology and Drug Design

Volumn 86, Issue 5, 2015, Pages 1178-1184

  Zhang, Yao ^a   Lee, Philbert ^b   Liang, Shichu ^a   Zhou, Zuping ^a   Wu, Xiaoyang ^b   Yang, Feng ^a   Liang, Hong ^a  

^a GUANGXI NORMAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

human serum albumin; non steroidal anti inflammatory drug; protein drug interaction; X ray crystallography

Indexed keywords

ARGININE; DICLOFENAC; HUMAN SERUM ALBUMIN; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BINDING; SERUM ALBUMIN;

ARTICLE; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR DOCKING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DICLOFENAC; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; SERUM ALBUMIN;

EID: 84944155489     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12583     Document Type: Article

References (38)

1. Peters T., (1995) All About Albumin: Biochemistry, Genetics and Medical Applications. San Diego: Academic Press.
2. Yamasaki K., Chuang V.T., Maruyama T., Otagiri M., (2013) Albumin-drug interaction and its clinical implication. Biochim Biophys Acta; 1830: 5435-5443.
3. Neumann E., Frei E., Funk D., Becker M.D., Schrenk H.H., Müller-Ladner U., Fiehn C., (2010) Native albumin for targeted drug delivery. Expert Opin Drug Deliv; 7: 915-925.
4. Kratz F., Elsadek B., (2012) Clinical impact of serum proteins on drug delivery. J Control Release; 161: 429-445.
5. Kratz F., (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release; 132: 171-183.
6. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S., (2005) Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol; 353: 38-52.
7. Yang F., Bian C., Huang M., (2007) Effect of human serum albumin on drug metabolism: structural evidence of esterase activity of human serum albumin. J Struct Biol; 157: 348-355.
8. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P., (2012) Human serum albumin: from bench to bedside. Mol Aspects Med; 33: 209-290.
9. He X.M., Carter D.C., (1992) Atomic structure and chemistry of human serum albumin. Nature; 358: 209-215.
10. Sudlow G., Birkett D.J., Wade D.N., (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol; 11: 824-832.
11. Petitpas I., Bhattacharya A.A., Twine S., East M., Curry S., (2001) Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem; 276: 22804-22809.
12. Curry S., (2009) Lessons from the crystallographic analysis of small molecule binding to human serum albumin. Drug Metab Pharmacokinet; 24: 342-357.
13. Stewart A.J., Blindauer C.A., Berezenko S., Sleep D., Sadler P.J., (2003) Interdomain zinc site on human albumin. Proc Natl Acad Sci USA; 100: 3701-3706.
14. Zunszain P.A., Ghuman J., McDonagh A.F., Curry S., (2008) Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J Mol Biol; 381: 394-406.
15. Li M., Lee P., Zhang Y., Ma Z., Yang F., Zhou Z., Wu X., Liang H., (2014) X-ray crystallographic and fluorometric analysis of the interactions of rhein to human serum albumin. Chem Biol Drug Des; 83: 167-173.
16. Zhang Y., Ho A., Yue J., Kong L., Zhou Z., Wu X., Yang F., Liang H., (2014) Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. Eur J Med Chem; 86: 449-455.
17. Luo Z., Shi X., Hu Q., Zhao B., Huang M., (2012) Structural evidence of perfluorooctane sulfonate transport by human serum albumin. Chem Res Toxicol; 25: 990-992.
18. Wang Y., Yu H., Shi X., Luo Z., Lin D., Huang M., (2013) Structural mechanism of ring-opening reaction of glucose by human serum albumin. J Biol Chem; 288: 15980-15987.
19. Yang F., Lee P., Ma Z., Ma L., Yang G., Wu X., Liang H., (2013) Regulation of amantadine hydrochloride binding with IIA subdomain of human serum albumin by fatty acid chains. J Pharm Sci; 102: 84-92.
20. Hein K.L., Kragh-Hansen U., Morth J.P., Jeppesen M.D., Otzen D., Møller J.V., Nissen P., (2011) Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J Struct Biol; 171: 353-360.
21. Yang F., Yue J., Ma L., Ma Z., Li M., Wu X., Liang H., (2012) Interactive associations of drug-drug and drug-drug-drug with IIA subdomain of human serum albumin. Mol Pharm; 9: 3259-3265.
22. Zhu L., Yang F., Chen L., Meehan E.J., Huang M., (2008) A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J Struct Biol; 162: 40-49.
23. Simard J.R., Zunszain P.A., Ha C.E., Yang J.S., Bhagavan N.V., Petitpas I., Curry S., Hamilton J.A., (2005) Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci USA; 102: 17958-17963.
24. Abou-Zied O.K., AlShih O.I., (2008) Characterization of subdomain IIA binding site of human serum albumin in its native, unfolded, and refolded states using small molecular probes. J Am Chem Soc; 130: 10793-10801.
25. Zsila F., (2013) Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model. Mol Pharm; 10: 1668-1682.
26. Vallianatou T., Lambrinidis G., Tsantili-Kakoulidou A., (2013) In silico prediction of human serum albumin binding for drug leads. Expert Opin Drug Discov; 8: 583-895.
27. Miedzybrodzki R., (2004) Trends in nonsteroidal anti-inflammatory drug development and application. Postepy Hig Med Dosw; 58: 438-448.
28. Wolfe M.M., Lichtenstein D.R., Singh G., (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med; 340: 1888-1899.
29. Chamouard J.M., Barre J., Urien S., Houin G., Tillement J.P., (1985) Diclofenac binding to albumin and lipoproteins in human serum. Biochem Pharmacol; 34: 1695-1700.
30. Liang H., Yang F., Lee N., Wu X., (2014) HSA-based anti-inflammatory therapy: a new and improved approach. Future Med Chem; 6: 119-121.
31. Curry S., et al,. (1998) Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol; 5: 827-835.
32. DeLano W.L., (2004) The PyMOL Molecular Graphics System. San Carlos, CA: DeLano Scientific.
33. Bhattacharya A.A., Grune T., Curry S., (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol; 303: 721-732.
34. Yamaguchi S., Aldini G., Ito S., Morishita N., Shibata T., Vistoli G., Carini M., Uchida K., (2010) Delta12-prostaglandin J2 as a product and ligand of human serum albumin: formation of an unusual covalent adduct at His146. J Am Chem Soc; 132: 824-832.
35. Colmenarejo G., (2003) In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev; 3: 275-301.
36. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Rosenberg S.H., et al,. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature; 435: 677-681.
37. Elsadek B., Kratz F., (2012) Impact of albumin on drug delivery-new applications on the horizon. J Control Release; 157: 4-28.
38. Gokara M., Sudhamalla B., Amooru D.G., Subramanyam R., (2010) Molecular interaction studies of trimethoxy flavone with human serum albumin. PLoS ONE; 1: 8834-8842.